Wound Management Technologies Announces Second Quarter Financial Results and Finalization...

Wound Management Technologies Announces Second Quarter Financial Results and
Finalization of Due Diligence on BioPharma

FORT WORTH, Texas, Aug. 17 /PRNewswire-FirstCall/ -- Wound Management
Technologies, Inc., (the "Company") (OTC Bulletin Board: WNDM), a rapidly
growing provider of specialty medical devices and products, announced
financial results for the second quarter 2009.

The Company reported a net loss of $323,911, or $0.01 per share for the second
quarter 2009, compared to a net loss of $233,505, or $0.01 per share for the
second quarter ending June 30, 2008.

The Company incurred a net loss in the six months ended June 30, 2009 of
$810,536 compared to a net loss of $586,738 in the same period in 2008. The
increase of the net loss for the six months ended June 30, 2009, compared to
the same period in 2008 resulted primarily due to an increase in cost of goods
resulting from new compliance regulations through CMS. In November 2008
Medicare announced that all gel products would need to be sterile. Wound Care
Innovations, LLC, the wholly owned subsidiary of the Company which markets and
distributes the advanced wound care collagen product, CellerateRx(R) began and
completed all necessary sterility tests for their wound care gel. Packaging
changes in the 1 gram and 5 gram powder and packers were also completed. The
Company also spent this time further expanding its data file of evidence-based
studies. "We are pleased that these issues have all been resolved as we move
forward," states Scott Haire, the Company's CEO. "We can now re-focus on
increasing sales both domestically and internationally."

"Unfortunately, these changes diverted our focus from sales to ensuring that
our products were in compliance with changing CMS standards," continued Haire.
"This, coupled with our emphasis on increasing our clinicals showing that
CellerateRx(R) products are unique in the wound care market, slowed our sales
production during the first half of the year."

The Company is also in its final stages of due diligence with BioPharma, and
anticipates closing the acquisition early in the third quarter. The Company
believes that the complimentary technologies of BioPharma and its future
products should strengthen the company's sales both domestically and
internationally and move it closer to becoming cash flow positive. Once this
acquisition closes, the Company plans on refocusing efforts toward increasing
revenues through strategic alliances with major sales organizations and
launching additional products into these large sales organizations.

About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in Fort Worth, Texas, markets and distributes
collagen-based wound care products to the healthcare market under exclusive
world-wide distribution rights to the patented technology licensed to the
company. The company is positioned and seeks to be a leading global provider
of wound care products. For more information on the company please visit the
company's website at www.celleraterx.com.

For Product Information: For Investor/Shareholder Relations:
Cathy Bradshaw 954-315-9242 Lucy Singleton 817-820-7080

Safe Harbor Statement Under The Private Securities Litigation Reform Act of
1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.

SOURCE Wound Management Technologies, Inc.

For Product Information: Cathy Bradshaw, +1-954-315-9242; For Investor -
Shareholder Relations: Lucy Singleton, +1-817-820-7080, both of Wound
Management Technologies, Inc.